NASDAQ:EDIT - Editas Medicine Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $27.89
  • Forecasted Upside: 48.58 %
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.77
▲ +0.68 (3.76%)

This chart shows the closing price for EDIT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Editas Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDIT

Analyst Price Target is $27.89
▲ +48.58% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $27.89, with a high forecast of $60.00 and a low forecast of $8.00. The average price target represents a 48.58% upside from the last price of $18.77.

This chart shows the closing price for EDIT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Editas Medicine. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 2 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 3 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 3 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 3 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 3 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2022BarclaysBoost Price TargetEqual Weight$16.00 ➝ $17.00Low
5/24/2022The Goldman Sachs GroupLower Price TargetSell$10.00 ➝ $8.00Medium
5/5/2022OppenheimerLower Price Target$55.00 ➝ $28.00High
4/18/2022Robert W. BairdLower Price Target$44.00 ➝ $33.00High
4/12/2022Morgan StanleyBoost Price TargetUnderweight$16.00 ➝ $17.00Medium
2/25/2022BarclaysLower Price Target$39.00 ➝ $18.00High
2/25/2022Chardan CapitalLower Price TargetBuy$75.00 ➝ $60.00High
2/25/2022OppenheimerLower Price TargetOutperform$80.00 ➝ $55.00High
2/25/2022SVB LeerinkLower Price TargetMarket Perform$41.00 ➝ $27.00High
2/11/2022Evercore ISIDowngradeHold$15.00High
1/6/2022Morgan StanleyLower Price TargetUnderweight$37.00 ➝ $24.00Low
10/20/2021Robert W. BairdReiterated RatingBuyMedium
10/19/2021SVB LeerinkInitiated CoverageMarket Perform$41.00Medium
9/30/2021Chardan CapitalReiterated RatingBuy$75.00Medium
9/30/2021Stifel NicolausLower Price TargetHold$65.00 ➝ $46.00High
9/23/2021Stifel NicolausInitiated CoverageHold$65.00High
9/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$42.00 ➝ $80.00Medium
8/9/2021Truist FinancialUpgradeBuy$80.00Low
8/5/2021Evercore ISIUpgradeUnderperform ➝ Outperform$20.00 ➝ $60.00High
7/7/2021Chardan CapitalReiterated RatingBuyMedium
5/10/2021Morgan StanleyLower Price TargetUnderweight$40.00 ➝ $37.00High
5/3/2021Royal Bank of CanadaInitiated CoverageSector Perform$40.00High
4/16/2021The Goldman Sachs GroupInitiated CoverageSell$20.00High
3/22/2021Credit Suisse GroupInitiated CoverageOutperform$58.00High
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$46.00Medium
3/2/2021Morgan StanleyLower Price TargetUnderweight$45.00 ➝ $40.00Medium
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$46.00Low
2/28/2021JPMorgan Chase & Co.Reiterated RatingSell$30.00Low
2/26/2021Truist FinancialDowngradeBuy ➝ Hold$45.00Low
2/25/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00Medium
2/10/2021Chardan CapitalBoost Price TargetBuy$55.00 ➝ $77.00Low
1/20/2021JPMorgan Chase & Co.Reiterated RatingHoldLow
1/19/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$64.00 ➝ $45.00Low
1/13/2021Wells Fargo & CompanyBoost Price TargetOverweight$69.00 ➝ $86.00Medium
1/7/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
12/16/2020Morgan StanleyBoost Price TargetEqual Weight$30.00 ➝ $64.00Low
12/10/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$28.00 ➝ $69.00High
11/11/2020Morgan StanleyLower Price TargetEqual Weight$31.00 ➝ $30.00High
11/6/2020Raymond JamesLower Price TargetOutperform$65.00 ➝ $60.00Medium
11/2/2020Robert W. BairdInitiated CoverageUnderperform$14.00High
10/13/2020Morgan StanleyLower Price TargetEqual Weight$32.00 ➝ $31.00Medium
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$27.00 ➝ $32.00Low
8/7/2020Raymond JamesBoost Price TargetOutperform$46.00 ➝ $65.00High
6/18/2020SunTrust BanksInitiated CoverageBuy$45.00High
6/15/2020OppenheimerReiterated RatingHoldHigh
6/12/2020Chardan CapitalReiterated RatingBuy$55.00High
5/11/2020Morgan StanleyLower Price TargetEqual Weight$30.00 ➝ $27.00High
5/7/2020OppenheimerInitiated CoverageHoldMedium
3/4/2020Chardan CapitalReiterated RatingBuy$55.00High
2/27/2020Raymond JamesLower Price TargetOutperform$44.00 ➝ $41.00High
2/27/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
2/21/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$28.00High
12/10/2019Chardan CapitalReiterated RatingBuy$55.00Low
8/9/2019Morgan StanleySet Price TargetHold$29.00High
7/25/2019Chardan CapitalReiterated RatingBuy$55.00Medium
6/16/2019Chardan CapitalSet Price TargetBuy$55.00Medium
5/8/2019OppenheimerReiterated RatingHoldMedium
4/11/2019Evercore ISIInitiated CoverageOutperformMedium
2/7/2019BTIG ResearchInitiated CoverageBuy$30.00Low
1/22/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
1/22/2019CowenReiterated RatingBuyMedium
1/22/2019Chardan CapitalReiterated RatingBuy$55.00High
1/10/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
12/31/2018SunTrust BanksReiterated RatingBuyHigh
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
9/21/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$40.00High
8/6/2018JPMorgan Chase & Co.Set Price TargetHold$36.00High
5/15/2018Chardan CapitalLower Price TargetBuy$72.50 ➝ $55.00Low
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$28.00 ➝ $43.00Low
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $46.00Medium
3/7/2018JMP SecuritiesBoost Price TargetOutperform$40.00 ➝ $67.00High
2/13/2018CLSAInitiated CoverageUnderperform ➝ UnderperformLow
1/23/2018SunTrust BanksUpgradeHold ➝ Buy$17.00 ➝ $45.00High
11/7/2017CowenReiterated RatingBuyN/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 ➝ $28.00N/A
9/6/2017BarclaysInitiated CoverageOverweight$19.69 ➝ $28.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/13/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
3/15/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 0 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Editas Medicine logo
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $18.77
Low: $17.83
High: $19.03

50 Day Range

MA: $14.44
Low: $10.00
High: $19.42

52 Week Range

Now: $18.77
Low: $9.59
High: $73.03

Volume

1,477,692 shs

Average Volume

1,795,990 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Editas Medicine?

The following Wall Street analysts have issued reports on Editas Medicine in the last year: Barclays PLC, Chardan Capital, Evercore ISI, Morgan Stanley, Oppenheimer Holdings Inc., Robert W. Baird, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for EDIT.

What is the current price target for Editas Medicine?

9 Wall Street analysts have set twelve-month price targets for Editas Medicine in the last year. Their average twelve-month price target is $27.89, suggesting a possible upside of 48.2%. Chardan Capital has the highest price target set, predicting EDIT will reach $60.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $8.00 for Editas Medicine in the next year.
View the latest price targets for EDIT.

What is the current consensus analyst rating for Editas Medicine?

Editas Medicine currently has 2 sell ratings, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EDIT, but not buy more shares or sell existing shares.
View the latest ratings for EDIT.

What other companies compete with Editas Medicine?

Other companies that are similar to Editas Medicine include Vericel, Valneva, Exscientia, SpringWorks Therapeutics and Alector. Learn More about companies similar to Editas Medicine.

How do I contact Editas Medicine's investor relations team?

Editas Medicine's physical mailing address is 11 Hurley Street, Cambridge MA, 02141. The company's listed phone number is (617) 401-9000 and its investor relations email address is [email protected] The official website for Editas Medicine is www.editasmedicine.com. Learn More about contacing Editas Medicine investor relations.